Home / Life Stages

Perimenopause, menopause, and what comes after

These stages blur into each other more than most marketing admits. Here's what the research actually defines, stage by stage.

Lavender field
Stage 1

Perimenopause

Typically starts in the mid-to-late 40s, though it can begin earlier

The transition itself, not a single event — defined by the STRAW+10 staging framework (widely used by NIA and NAMS) based on menstrual cycle changes and hormone patterns rather than a fixed age. The landmark SWAN study, which followed thousands of women through this transition, found symptom timing and severity varies enormously between individuals.

FSH (follicle-stimulating hormone) testing is often used to gauge where someone is in the transition, but levels fluctuate significantly during perimenopause — a single test can be misleading, which is part of why diagnosis relies more on symptom pattern and cycle changes than on one lab value.

Key sources: STRAW+10 staging system (NIA/NAMS); SWAN (Study of Women's Health Across the Nation)
Stage 2

Menopause

Clinically defined as 12 consecutive months without a period

Menopause itself is a single point in time, not a phase — it's diagnosed retrospectively, only once a full year has passed without a menstrual period. Everything before that point is perimenopause; everything after is postmenopause. The average age in the U.S. is 51, though the range is wide and influenced by genetics, smoking history, and other factors.

Key sources: ACOG and NAMS clinical definitions of menopause
Stage 3

Postmenopause

Begins one year after the final period, and continues for the rest of life

Two changes become more clinically significant here. Bone density loss accelerates — roughly 1–2% per year on average, and up to 20% total within 5–7 years of the final period, which is why bone-support nutrients and load-bearing exercise matter more in this stage. Cardiovascular risk also rises as estrogen's earlier protective effect fades.

Hormone therapy's risk-benefit picture shifts here too. The "timing hypothesis" — supported by NAMS' 2017 position statement and the 2016 KEEPS trial published in the New England Journal of Medicine — suggests HRT started closer to menopause onset carries a different risk profile than starting it many years into postmenopause. A 2013 study by Maki in the journal Menopause found similar timing-dependent effects on cognitive outcomes. This is genuinely a conversation to have with a clinician, not something to self-manage with supplements alone.

Key sources: NAMS 2017 Hormone Therapy Position Statement; Harman et al. (KEEPS), NEJM 2016; Maki, Menopause 2013
This page is educational, not medical advice. If you're navigating any of these stages and have questions about your specific symptoms, timeline, or options, please talk with a licensed clinician — a gynecologist, a menopause-certified provider, or your primary care doctor.